These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27175649)

  • 1. Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study.
    Restuccia G; Boiardi L; Cavazza A; Catanoso M; Macchioni P; Muratore F; Cimino L; Aldigeri R; Crescentini F; Pipitone N; Salvarani C
    Medicine (Baltimore); 2016 May; 95(19):e3524. PubMed ID: 27175649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study.
    Muratore F; Boiardi L; Restuccia G; Cavazza A; Catanoso M; Macchioni P; Spaggiari L; Cimino L; Aldigeri R; Pipitone N; Fontana A; Casali M; Croci S; Salvarani C
    Semin Arthritis Rheum; 2020 Aug; 50(4):549-558. PubMed ID: 32446023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study.
    Restuccia G; Boiardi L; Cavazza A; Catanoso M; Macchioni P; Muratore F; Soriano A; Cimino L; Aldigeri R; Crescentini F; Pipitone N; Salvarani C
    J Autoimmun; 2017 Feb; 77():39-44. PubMed ID: 27742223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain.
    Martinez-Lado L; Calviño-Díaz C; Piñeiro A; Dierssen T; Vazquez-Rodriguez TR; Miranda-Filloy JA; Lopez-Diaz MJ; Blanco R; Llorca J; Gonzalez-Gay MA
    Medicine (Baltimore); 2011 May; 90(3):186-193. PubMed ID: 21512412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients.
    Alba MA; García-Martínez A; Prieto-González S; Tavera-Bahillo I; Corbera-Bellalta M; Planas-Rigol E; Espígol-Frigolé G; Butjosa M; Hernández-Rodríguez J; Cid MC
    Medicine (Baltimore); 2014 Jul; 93(5):194-201. PubMed ID: 25181312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Takayasu arteritis and large-vessel giant cell arteritis in Italian population. Comprehensive analysis from a single institutional cohort of 184 cases.
    Boiardi L; Galli E; Macchioni P; Muratore F; Klinowski G; Hunder GG; Casali M; Besutti G; Spaggiari L; Versari A; Croci S; Mancuso P; Rossi PG; Marvisi C; Salvarani C
    Semin Arthritis Rheum; 2023 Apr; 59():152173. PubMed ID: 36780709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis.
    Jakobsson K; Jacobsson L; Mohammad AJ; Nilsson JÅ; Warrington K; Matteson EL; Turesson C
    BMC Musculoskelet Disord; 2016 Aug; 17(1):363. PubMed ID: 27558589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study.
    Samson M; Devilliers H; Ly KH; Maurier F; Bienvenu B; Terrier B; Charles P; Guillevin L; Besancenot JF; Liozon E; Fauchais AL; Loffroy R; Binquet C; Audia S; Seror R; Mariette X; Bonnotte B
    Eur J Intern Med; 2018 Nov; 57():96-104. PubMed ID: 30054122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study.
    Labarca C; Koster MJ; Crowson CS; Makol A; Ytterberg SR; Matteson EL; Warrington KJ
    Rheumatology (Oxford); 2016 Feb; 55(2):347-56. PubMed ID: 26385368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis.
    Alba MA; García-Martínez A; Prieto-González S; Espígol-Frigolé G; Butjosa M; Tavera-Bahillo I; Rodríguez-Pintó I; Hernández-Rodríguez J; Cid MC
    Semin Arthritis Rheum; 2014 Jun; 43(6):772-7. PubMed ID: 24315461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A Case-Control Study.
    Delaval L; Samson M; Schein F; Agard C; Tréfond L; Deroux A; Dupuy H; Garrouste C; Godmer P; Landron C; Maurier F; le Guenno G; Rieu V; Desblache J; Durel CA; Jousselin-Mahr L; Kassem H; Pugnet G; Queyrel V; Swiader L; Blockmans D; Sacré K; Lazaro E; Mouthon L; Aumaître O; Cathébras P; Guillevin L; Terrier B;
    Arthritis Rheumatol; 2021 Feb; 73(2):286-294. PubMed ID: 32951354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis.
    Muratore F; Boiardi L; Cavazza A; Aldigeri R; Pipitone N; Restuccia G; Bellafiore S; Cimino L; Salvarani C
    J Autoimmun; 2016 May; 69():94-101. PubMed ID: 27009904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study.
    Macchioni P; Boiardi L; Muratore F; Restuccia G; Cavazza A; Pipitone N; Catanoso M; Mancuso P; Luberto F; Giorgi Rossi P; Salvarani C
    Rheumatology (Oxford); 2019 Apr; 58(4):609-616. PubMed ID: 30517710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
    van der Veen MJ; Dinant HJ; van Booma-Frankfort C; van Albada-Kuipers GA; Bijlsma JW
    Ann Rheum Dis; 1996 Apr; 55(4):218-23. PubMed ID: 8733437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis.
    Hernández-Rodríguez J; García-Martínez A; Casademont J; Filella X; Esteban MJ; López-Soto A; Fernández-Solà J; Urbano-Márquez A; Grau JM; Cid MC
    Arthritis Rheum; 2002 Feb; 47(1):29-35. PubMed ID: 11932875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Giant cell arteritis: a multicenter observational study in Brazil.
    Souza AW; Okamoto KY; Abrantes F; Schau B; Bacchiega AB; Shinjo SK
    Clinics (Sao Paulo); 2013; 68(3):317-22. PubMed ID: 23644850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The U.S. Veterans Health Administration national giant cell arteritis (GCA) database cohort: incident ophthalmic complications in biopsy-negative GCA patients.
    Chung SH; Morcos MB; Pollock PS; Ng B
    Clin Rheumatol; 2021 Jul; 40(7):2829-2833. PubMed ID: 33417014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eosinophilic giant cell arteritis: A different subset of disease?
    Boiardi L; Marvisi C; Macchioni P; Cavazza A; Croci S; Besutti G; Spaggiari L; Giorgi Rossi P; Cimino L; Pipitone N; Ricordi C; Muratore F; Salvarani C
    Semin Arthritis Rheum; 2024 Apr; 65():152409. PubMed ID: 38350341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Giant cell arteritis: diagnostic accuracy of MR imaging of superficial cranial arteries in initial diagnosis-results from a multicenter trial.
    Klink T; Geiger J; Both M; Ness T; Heinzelmann S; Reinhard M; Holl-Ulrich K; Duwendag D; Vaith P; Bley TA
    Radiology; 2014 Dec; 273(3):844-52. PubMed ID: 25102371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
    Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
    Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.